

TÜV Rheinland LGA Products GmbH • 51105 Köln

*Immucor GTI Diagnostics*  
20925 Crossroads Circle  
53186, Waukesha, WI  
USA

Contact

Tel. +49 911 655-5225  
Mail: [service@de.tuv.com](mailto:service@de.tuv.com)

Date May 22, 2025

**Notified Body Confirmation Letter**

Reference.: IMMUC\_GTI\_PDQ1\_HX\_20250514\_FINAL SIGNED - Order: 1190894

To whom it may concern,

**Confirmation of the status of a formal application, written agreement, and appropriate surveillance in the framework of Regulation (EU) 2024/1860 amending Regulations (EU) 2017/745 and (EU) 2017/746 as regards the transitional provisions for certain in vitro diagnostic medical devices.**

This letter confirms that **TÜV Rheinland LGA Products GmbH**, a Notified Body (NB) designated against Regulation (EU) 2017/746 (IVDR) and identified by the number **0197** on NANDO, has received a formal application in accordance with Section 4.3, first subparagraph of Annex VII of IVDR and has signed a written agreement in accordance with Section 4.3, second subparagraph of Annex VII of IVDR with the following manufacturer:

Immucor GTI Diagnostics  
20925 Crossroads Circle  
53186, Waukesha, WI  
USA  
SRN Number: US-MF-000020921

The devices covered by the formal application and the written agreement mentioned above are identified in the tables below. Table 1 identifies the devices for which an IVDR application has been received, written agreement concluded and for which the NB is also responsible for appropriate surveillance under the applicable Directive 98/79/EC. Table 2 identifies the devices for which an IVDR application has been received and a written agreement concluded, but the NB has not yet taken the responsibility for appropriate surveillance of the corresponding devices under the applicable Directive 98/79/EC.

In the case of devices covered by certificates issued under Directive 98/79/EC (IVDD) that expired after May 26, 2022 and before July 9, 2024, without having been withdrawn, this letter also confirms that the manufacturer either signed the written agreement under IVDR by the date of IVDD certificate expiry; or provided evidence that a competent authority of a Member State had granted a derogation or exemption from the applicable conformity assessment procedure in accordance with Article 54 of IVDR or Article 92 of the IVDR respectively, by July 9, 2024 for the relevant devices.

TÜV Rheinland  
LGA Products GmbH

Am Grauen Stein  
51105 Köln  
Germany

Headquarter

Tillystraße 2  
90431 Nuremberg

Phone. +49 911 655 5225  
Fax +49 911 655 5226  
[service@de.tuv.com](mailto:service@de.tuv.com)  
[www.tuv.com/safety](http://www.tuv.com/safety)

Board of Management

Dipl.-Ing.  
Thomas Weigand, Spokesman

Dipl.-Kfm.  
Dr. Jörg Schlösser

Nuremberg HRB 26013  
VAT No.: DE 811835490

Chairman of the  
Supervisory Board

Dr.-Ing. Michael Fübi

The transition timelines that apply to the devices covered by this letter, subject to the manufacturer's continued compliance to the other conditions specified in Article 110.3c of IVDR (as amended by (EU) 2024/1860), are shown below:

- 31 December 2027 for devices covered by an IVDD certificate regardless of their risk class under the IVDR
- For devices not requiring the involvement of a notified body under the IVDD, but requiring it under the IVDR and for which a declaration of conformity was drawn up prior to 26 May 2022 in accordance with Directive 98/79/EC, the following dates apply:
  - 31 December 2027, for class D devices;
  - 31 December 2028, for class C devices;
  - 31 December 2029, for class B devices and for class A devices placed on the market in sterile condition

On behalf of the Notified Body



Katja Mierisch

Certification body

**Table 1: Devices covered by this letter and for which the NB is also responsible for appropriate surveillance of the corresponding devices under the applicable Directive 98/79/EC:**

Device name or Basic UDI-DI (under IVDR application)	IVDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the IVDR device is a substitute device, identification of the corresponding IVDD device	IVDD Certificate Reference(s) of the devices under IVDR application, and the NB Identification
LIFECODES HLA-A eRES SSO Typing Kit	Class C	N/A	HL 1804149-1 NB 0197
LIFECODES HLA-B eRES Typing Kit	Class C	N/A	HL 1804149-1 NB 0197
LIFECODES HLA-C eRES SSO Typing Kit	Class C	N/A	HL 1804149-1 NB 0197
LIFECODES HLA-DRB1 eRES SSO Typing Kit	Class C	N/A	HL 1804149-1 NB 0197
LIFECODES HLA-DRB 3,4,5 SSO Typing Kit	Class C	N/A	HL 1804149-1 NB 0197

**Table 2: Devices covered by this letter and for which the NB is NOT responsible for appropriate surveillance of the corresponding devices under the applicable Directive 98/79/EC:**

Device name or Basic UDI-DI (under IVDR application)	IVDR Device classification (as proposed by the manufacturer and verified at the pre-application stage)	If the IVDR device is a substitute device, identification of the corresponding IVDD device	IVDD Certificate Reference(s) of the devices under IVDR application, and the NB Identification
<b>LIFECODES HLA-DQA1/B1 SSO Typing Kit</b>	Class C	N/A	N/A - Device did not require a Notified Body certificate under Directive
<b>LIFECODES HLA-DPA1/B1 SSO Typing Kit</b>	Class C	N/A	N/A - Device did not require a Notified Body certificate under Directive
<b>LIFECODES C3d Detection</b>	Class C	N/A	N/A - Device did not require a Notified Body certificate under Directive

#### Confirmation Letter Revision History

Date	NB internal reference traceable to each version of the letter	Action
2025-05-22	Order no. 1190894	Initial issue